Month: June 2020

Brussels, June 24, 2020 – Solvay today provides a trading update for the second quarter, highlighting resilience amid the COVID-19 global pandemic.As indicated in early May and following the strong performance in the first quarter, market headwinds increased sharply in the second quarter. Businesses related to oil and gas, automotive, and aerospace were the most significantly impacted, with revenues down about 40%, whereas businesses related to construction and mining were down about 20%. Other key markets such as healthcare, agro/food, home & personal care and electronics resisted well and helped to offset some of the challenged markets. Against that backdrop, Group sales were down 20% in aggregate across April and May versus 2019 levels, reflecting the resilience of Solvay’s diversified portfolio. Similar demand trends are expected...

Brussel, 24 juni 2020 – Solvay geeft vandaag een marktupdate over het tweede kwartaal en benadrukt de veerkracht te midden van de COVID-19-pandemie.Zoals werd aangekondigd in mei en volgend op de sterke prestaties in het eerste kwartaal kende het tweede kwartaal veel meer economische tegenwind. Activiteiten in de olie- en gassector, de auto-industrie en de luchtvaart werden het zwaarst getroffen, met een omzetdaling van ongeveer 40%, terwijl de activiteiten in de bouw- en mijnbouwsector een daling van ongeveer 20% te kennen gaven. Andere belangrijke markten, zoals gezondheidszorg, agro/voeding, huishoudelijke & persoonlijke verzorging en elektronica hebben zich goed staande gehouden en hielpen om een aantal van de meer geïmpacteerde markten te compenseren. Tegen die achtergrond is de totale omzet van de Groep in april en mei...

Bruxelles, 24 juin 2020 – Solvay fait un point à date sur la situation de ses principaux marchés au cours de ce second trimestre, démontrant sa résilience dans le contexte de la crise sanitaire mondiale liée au COVID-19.Comme indiqué début mai, lors de la publication de l’activité du premier trimestre et après une performance solide au cours de ce trimestre, les vents contraires se sont renforcés au cours du second trimestre. Les activités liées aux secteurs du pétrole et du gaz, l’automobile et l’aéronautique ont été les plus impactées, avec des baisses de chiffre d’affaires d’environ 40%. Les activités minières ainsi que dans le bâtiment/construction reculent d’environ 20%. Les activités liées à la santé, l’agroalimentaire, “home & personal care” et l’électronique ont été relativement résilientes et ont permis d’atténuer...

Innate Pharma to re-activate TELLOMAK trial in the USNew GMP-certified batch has been successfully manufacturedConference call to be held today on the lacutamab clinical trial program MARSEILLE, France, June 24, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab TELLOMAK Phase II clinical trial, evaluating the efficacy and safety of lacutamab (formerly IPH4102) in patients with advanced T-cell lymphomas. The FDA decision is based on a quality assessment of a new Good Manufacturing Practice (GMP)-certified batch that has been successfully manufactured for the lacutamab clinical development program, including the TELLOMAK trial. The...

WISeKey Appoints Philippe Gerwill to its Advisory CommitteeGeneva – June 24, 2020 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / NASDAQ: WKEY), a leading cybersecurity and IoT company, today announced the appointment  of Philippe Gerwill to its Advisory Committee. Members of WISeKey’s Advisory Committee originate from a wide variety of sectors that are of critical importance to WISeKey’s growth strategy, including Cybersecurity, IoT, Blockchain, and information technology.

Orphazyme A/SCompany announcement                                                                                      No. 36/2020                                                                                                          Company Registration No. 32266355 Arimoclomol demonstrated a marked and clinically meaningful dose-dependent reduction in liver and spleen sizePrimary endpoint demonstrating relative reduction in chitotriosidase levels from baseline was observed, although did not achieve statistical significanceData supports Orphazyme’s intention to proceed with pivotal stage clinical development in Gaucher diseaseCopenhagen, Denmark, June 24, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces...

Innate Pharma to re-activate TELLOMAK trial in the USNew GMP-certified batch has been successfully manufacturedConference call to be held today on the lacutamab clinical trial program Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab TELLOMAK Phase II clinical trial, evaluating the efficacy and safety of lacutamab (formerly IPH4102) in patients with advanced T-cell lymphomas. The FDA decision is based on a quality assessment of a new Good Manufacturing Practice (GMP)-certified batch that has been successfully manufactured for the lacutamab clinical development program, including the TELLOMAK trial. The Company can now resume recruitment of new patients in the...